Patterns of Medication Initiation and Continuation Impacting Cognitive Function in Elderly Patients - Top-Institutions - MDSpire

Patterns of Medication Initiation and Continuation Impacting Cognitive Function in Elderly Patients

  • By

  • Dan P. Ly

  • Annie W. Yang

  • Mei Leng

  • Catherine Sarkisian

  • Cheryl L. Damberg

  • John N. Mafi

  • April 28, 2026

  • 0 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    University of California, Los Angeles (UCLA) Health
    University of California, Los Angeles (UCLA) Health

    Los Angeles, CA

    Key Differentiators

    • Geriatrics
    • Pharmacology
    • Epidemiology

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Geriatrics
    • Neurology
    • Pharmacology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Geriatrics
    • Neurology
    • Pharmacology

  • #4

    Massachusetts General Hospital (MGH) / Harvard Medical School
    Massachusetts General Hospital (MGH) / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Geriatrics
    • Psychiatry
    • Pharmacology

  • #5

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Geriatrics
    • Pharmacology
    • Epidemiology

Original Source(s)

Patterns of Medication Initiation and Continuation Impacting Cognitive Function in Elderly Patients

  • by Dan P. Ly, Annie W. Yang, Mei Leng, Catherine Sarkisian, Cheryl L. Damberg, John N. Mafi

  • April 28, 2026

Related Content

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

Exploring the Links Between Dietary Variety, Frailty, and Cognitive Abilities in Older Adults Residing in the Community: A Cross-Sectional Analysis from Turkey

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes